SMART2-HF模型预测动脉粥样硬化性心血管病患者的新发心力衰竭风险
该研究在7698例已确诊动脉粥样硬化性心血管病(ASCVD)且无既往心力衰竭的患者中开发SMART2-HF模型,用于估计10年及终身新发心力衰竭风险。
要点
- SMART2-HF可预测ASCVD患者10年及终身新发心力衰竭风险
- 模型仅使用常规临床特征,与SMART2复发风险模型预测因子一致
核心结论
- SMART2-HF模型可用于预测ASCVD患者的新发心力衰竭风险,并可作为指南推荐的SMART2复发心血管风险模型的补充工具。
研究设计与样本
- 开发队列来自UCC-SMART研究,共7698例已确诊ASCVD(冠状动脉、脑血管或外周动脉疾病,或腹主动脉瘤)且无既往心力衰竭的患者。
- 采用Cox比例风险模型,以年龄为时间尺度,纳入性别-预测因子交互作用,估计10年及终身新发心力衰竭风险,并校正非心力衰竭死亡的竞争风险。
主要发现
- UCC-SMART队列中位随访11.2年(四分位距6.1-16.4年),发生1031例新发心力衰竭事件(13%)。
- 外部验证中预测风险与观察到的发生率相匹配。
关键数值与推荐
- 新发心力衰竭定义为因心力衰竭住院或心力衰竭相关死亡。
- 预测因子仅限常规可获得的临床特征,并与同一人群中用于复发心血管风险的SMART2风险模型保持一致。
临床怎么用
- SMART2-HF可作为现有SMART2复发心血管风险模型的补充工具,用于ASCVD患者的心力衰竭风险评估。
- 模型适用于已确诊冠状动脉、脑血管或外周动脉疾病或腹主动脉瘤的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. METHODS: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. RESULTS: During a median follow-up of 11.2 years (interquartile range 6.1-16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674-.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. CONCLUSIONS: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.
引用
- Reitsma, Lim, Gynnild, et al. Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model. Eur Heart J. 2026. PMID: 41810961. doi:10.1093/eurheartj/ehag153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。